Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement.

× No keyword cloud information.

8 in total

1. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

Authors: Maria Trachana; Artemis Koutsonikoli; Evagelia Farmaki; Nikoleta Printza; Vasiliki Tzimouli; Fotios Papachristou
Journal: Rheumatol Int Date: 2011-11-19 Impact factor: 2.631

2. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors: L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal: Ann Rheum Dis Date: 2005-04 Impact factor: 19.103

Review 3. A perspective on B-cell-targeting therapy for SLE.

Authors: R John Looney; Jennifer Anolik; Inaki Sanz
Journal: Mod Rheumatol Date: 2009-08-08 Impact factor: 3.023

4. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

Authors: C Alejandro Arce-Salinas; Felipe Rodríguez-García; J Iván Gómez-Vargas
Journal: Rheumatol Int Date: 2011-01-22 Impact factor: 2.631

5. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors: Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal: Ann Rheum Dis Date: 2006-11-15 Impact factor: 19.103

Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement.

1. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

2. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Review 3. A perspective on B-cell-targeting therapy for SLE.

4. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

5. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Review 6. [Rituximab in treatment for neuroimmunological diseases].

7. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses.

8. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?